Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
Identified by CAS number 137525-51-0, BPC-157 meets documentation and traceability requirements expected by European academic, pharmaceutical, and private research institutions
Cenexa Labs has no affiliation with Professor Ng or Monash University, and this information does not constitute an endorsement of any products or services
Every qualifying order earns you 15% commission, paid monthly
Imura, Y., Nishida, M., Ogawa, Y., Takakura, Y., and Matsuzaki, K., Biochim